Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that interim data from the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with de novo poor-risk acute myelogenous leukemia (AML) had been presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in Chicago, Illinois.

At ASCO(R), data were presented in 85 evaluable patients. The median age of these patients was 73 years (range of 60-87 years). Ninety-five percent of patients had two or more risk factors associated with a poor prognosis in elderly AML and 74% had three or more risk factors. The most common risk factors were age greater than or equal to 70 (78% of patients), and cardiac and pulmonary dysfunction (73% and 76% of patients respectively). In addition, 47% of patients had unfavorable cytogenetics.

The overall complete response rate was 35% (22 CR and 8 CRp). 90% of responses occurred after first induction treatment. While follow-up is still ongoing, the median (range) of overall survival for responders was 6.3 months (1.7-16.4 months) and for all patients was 3.2 months (0.1-16.4 months).

The induction death rate within 30 days of first induction treatment was 14%. The majority of first induction deaths were either due to progression of disease or infection. Myelosuppression was the primary toxicity, with pneumonia, infection and sepsis and non-infectious pulmonary disorders (hypoxia and dyspnea) being the most common severe adverse events (greater than or equal to grade 3).

Dr. Gary Schiller, Professor of Medicine at the David Geffen School of Medicine at UCLA and a lead investigator on the study, said "The
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... July 31, 2014 Catylix, Inc. ( ... ( Milpitas, California ) announced today ... and commercialize new fluorination products and related chemistry. ... benefited from the use of substituents that are ... with polarity to improve binding and bioavailability. Fluorinated ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:8/1/2014)... 01, 2014 Over 20,000 entrepreneurs from ... the 2014 Market America | SHOP.COM International Convention at ... The annual event will introduce new products, technology, programs ... earning, and also feature a who’s who of celebrities. ... | SHOP.COM Executive Team, successful entrepreneurs and celebrity guests. ...
(Date:8/1/2014)... FL (PRWEB) August 01, 2014 Fitness is ... too much effort. From walking around the block to biking ... to do and easy to maintain throughout the year. The ... a fitness forward series which will feature special guests, tips ... and stay in shape. The series will air on most ...
(Date:8/1/2014)... August 01, 2014 We are ... ES-AMI on AWS Marketplace. EspressReport ES-AMI delivers enterprise ... at $0.50 per hour (AWS infrastructure charges apply). ... easy-to-use enterprise BI and operational reporting system with ... and ad hoc reporting. It allows users to ...
(Date:8/1/2014)... Register to join the webinar here: http://bit.ly/1lPZNI9 . ... record for life sciences investing. IPOs in the sector tripled ... all venture dollars spent in 2013. The result: biotech companies ... However, 2014 is proving more of a mixed bag of ... while life sciences IPOs are losing steam, M&A is expected ...
(Date:7/31/2014)... Serious buyer, Andrew Hawley, announces his search ... Owsley Bear Stanley, the King of Acid, created the ... to Hawley, “The Grateful Dead and Owsley teamed up ... San Francisco and Los Angeles in 1965. The 1965 ... of paper. They were a goldenrod yellow, blue, and ...
Breaking Medicine News(10 mins):Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 3Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 4Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 5Health News:Forbes Living to Air Fitness Forward Series 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
... surgeon John J. Callaghan, MD was elected to the Board ... ( http://www.aaos.org/ )(AAOS) at the organization,s 2009 Annual Meeting ... First Vice-President.Having to wear a cast as a young child, ... the field of orthopaedic surgery. "Breaking my arm taught ...
... time for ACL injuries in young athletesLAS VEGAS, Feb. ... Ligament (ACL) tears occur in the United States. ... Meeting of the American Academy of Orthopaedic Surgeons ... seen in younger patients as an increasing number of ...
... 25 February 2009 Molecular Oncology ... behalf of the Federation of European Biochemical Societies ... ISI), for inclusion in the Science Citation Index ... , MOLONC (published 6 times a year ...
... 25 The National Hospice and Palliative Care Organization ... Out" grants. Funded by the Department of Veterans Affairs, ... hospice and palliative care services for rural and homeless ... represent a range of community-based organizations. These providers ...
... Products Completely Safe, Include No Ingredients from PCA -NEW YORK, ... not affected by the Peanut Corporation of America (PCA) recall, ... any variety of KIND Fruit + Nut Bars or KIND ... that PCA is the focus of their investigation concerning a ...
... intergenerational program developed by OASIS to enlist older adults ... to eight cities during the next two years with ... promotes physical activity and healthy eating for low-income children ... grades 3 to 5 in after-school settings using teams ...
Cached Medicine News:Health News:John J. Callaghan, MD Elected Academy First Vice President 2Health News:John J. Callaghan, MD Elected Academy First Vice President 3Health News:An Athlete's First Question: 'Doc, When Can I Return?' 2Health News:An Athlete's First Question: 'Doc, When Can I Return?' 3Health News:Molecular Oncology accepted into Thomson Reuters index 2Health News:Grants to Increase Access to Hospice and Palliative Care for Rural and Homeless Veterans Awarded by National Hospice and Palliative Care Organization 2Health News:KIND Snacks Unaffected by Peanut Butter Recall 2Health News:WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program 2Health News:WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: